View Item 

Show simple item record

Minichromosome maintenance protein 7 and geminin expression: Prognostic value in laryngeal squamous cell carcinoma in patients treated with radiotherapy and cetuximab
dc.contributor.authorAlmadori, Giovanni
dc.contributor.authorLauriola, Libero
dc.contributor.authorColi, Antonella
dc.contributor.authorBussu, Francesco
dc.contributor.authorGallus, Roberto
dc.contributor.authorScannone, Domenico
dc.contributor.authorValentini, Vincenzo
dc.contributor.authorPaludetti, Gaetano
dc.contributor.authorCarey, Thomas E.
dc.contributor.authorRanelletti, Franco O.
dc.date.accessioned2017-04-14T15:10:41Z
dc.date.available2018-05-15T21:02:51Zen
dc.date.issued2017-04
dc.identifier.citationAlmadori, Giovanni; Lauriola, Libero; Coli, Antonella; Bussu, Francesco; Gallus, Roberto; Scannone, Domenico; Valentini, Vincenzo; Paludetti, Gaetano; Carey, Thomas E.; Ranelletti, Franco O. (2017). "Minichromosome maintenance protein 7 and geminin expression: Prognostic value in laryngeal squamous cell carcinoma in patients treated with radiotherapy and cetuximab." Head & Neck 39(4): 684-693.
dc.identifier.issn1043-3074
dc.identifier.issn1097-0347
dc.identifier.urihttps://hdl.handle.net/2027.42/136434
dc.description.abstractBackgroundMinichromosome maintenance protein 7 (MCM7) is a downstream of human epidermal growth receptor (HER1) signaling. We examined MCM7, geminin, and HER1 expression in patients with laryngeal squamous cell carcinoma (SCC) treated with radiotherapy and cetuximab.MethodsMCM7, geminin, and HER1 were evaluated by immunohistochemistry on 61 patients with laryngeal SCC. The follow‐up (median, 32.1 months; range, 2–139 months) went from the beginning of therapy to tumor progression‐free survival (PFS) and death (overall survival [OS]).ResultsMCM7, but not geminin, was associated only with HER1 expression, whereas no association was found with other clinicopathological characteristics. Patients with MCM7 high ‐ geminin high and MCM7 high ‐ geminin low tumor status had a risk of progression 3.1 times and 17.7 times greater, respectively, than patients with MCM7 low – geminin high tumor status. Tumor site, MCM7, and geminin were independent determinants of PFS, whereas MCM7 was an independent prognostic marker of OS.ConclusionMCM7‐geminin tumor status may be prognostic for patients with laryngeal SCC treated with cetuximab and radiotherapy. © 2016 Wiley Periodicals, Inc. Head Neck 39: 684–693, 2017
dc.publisherWiley Periodicals, Inc.
dc.subject.otherlaryngeal squamous cell carcinoma
dc.subject.othermini‐chromosome maintenance protein 7 (MCM7)
dc.subject.othercetuximab
dc.subject.otherradiotherapy
dc.subject.othergeminin
dc.titleMinichromosome maintenance protein 7 and geminin expression: Prognostic value in laryngeal squamous cell carcinoma in patients treated with radiotherapy and cetuximab
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOtolaryngology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/136434/1/hed24670.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/136434/2/hed24670_am.pdf
dc.identifier.doi10.1002/hed.24670
dc.identifier.sourceHead & Neck
dc.identifier.citedreferenceSaleh MN, Raisch KP, Stackhouse MA, et al. Combined modality therapy of A431 human epidermoid cancer using anti‐EGFr antibody C225 and radiation. Cancer Biother Radiopharm 1999; 14: 451 – 463.
dc.identifier.citedreferenceTachibana KE, Gonzalez MA, Coleman N. Cell‐cycle‐dependent regulation of DNA replication and its relevance to cancer pathology. J Pathol 2005; 205: 123 – 129.
dc.identifier.citedreferenceMcGarry TJ, Kirschner MW. Geminin, an inhibitor of DNA replication, is degraded during mitosis. Cell 1998; 93: 1043 – 1053.
dc.identifier.citedreferenceArentson E, Faloon P, Seo J, et al. Oncogenic potential of the DNA replication licensing protein CDT1. Oncogene 2002; 21: 1150 – 1158.
dc.identifier.citedreferenceYoshida K, Oyaizu N, Dutta A, Inoue I. The destruction box of human geminin is critical for proliferation and tumor growth in human colon cancer cells. Oncogene 2004; 23: 58 – 70.
dc.identifier.citedreferenceMaurizi M, Almadori G, Ferrandina G, et al. Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br J Cancer 1996; 74: 1253 – 1257.
dc.identifier.citedreferenceRubin Grandis J, Melhem MF, Gooding WE, et al. Levels of TGF‐alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998; 90: 824 – 832.
dc.identifier.citedreferenceAlmadori G, Cadoni G, Galli J, et al. Epidermal growth factor receptor expression in primary laryngeal cancer: an independent prognostic factor of neck node relapse. Int J Cancer 1999; 84: 188 – 191.
dc.identifier.citedreferenceBussu F, Ranelletti FO, Gessi M, et al. Immunohistochemical expression patterns of the HER4 receptors in normal mucosa and in laryngeal squamous cell carcinomas: antioncogenic significance of the HER4 protein in laryngeal squamous cell carcinoma. Laryngoscope 2012; 122: 1724 – 1733.
dc.identifier.citedreferenceAlmadori G, Bussu F, Gessi M, et al. Prognostic significance and clinical relevance of the expression of the HER family of type I receptor tyrosine kinases in human laryngeal squamous cell carcinoma. Eur J Cancer 2010; 46: 1144 – 1152.
dc.identifier.citedreferenceScambia G, Panici PB, Battaglia F, et al. Receptors for epidermal growth factor and steroid hormones in primary laryngeal tumors. Cancer 1991; 67: 1347 – 1351.
dc.identifier.citedreferenceAng KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002; 62: 7350 – 7356.
dc.identifier.citedreferenceGoldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995; 1: 1311 – 1318.
dc.identifier.citedreferenceBonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‐year survival data from a phase 3 randomised trial, and relation between cetuximab‐induced rash and survival. Lancet Oncol 2010; 11: 21 – 28.
dc.identifier.citedreferenceBonner JA, Raisch KP, Trummell HQ, et al. Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J Clin Oncol 2000; 18 ( 21 Suppl ): 47S – 53S.
dc.identifier.citedreferenceHuang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999; 59: 1935 – 1940.
dc.identifier.citedreferenceBussu F, Pozzoli G, Giglia V, et al. Effects of the administration of epidermal growth factor receptor specific inhibitor cetuximab, alone and in combination with cisplatin, on proliferation and apoptosis of Hep‐2 laryngeal cancer cells. J Laryngol Otol 2014; 128: 902 – 908.
dc.identifier.citedreferenceAng KK, Zhang Q, Rosenthal DI, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol 2014; 32: 2940 – 2950.
dc.identifier.citedreferenceHuang TH, Huo L, Wang YN, et al. Epidermal growth factor receptor potentiates MCM7‐mediated DNA replication through tyrosine phosphorylation of Lyn kinase in human cancers. Cancer Cell 2013; 23: 796 – 810.
dc.identifier.citedreferenceFerrandina G, Ranelletti FO, Gallotta V, et al. Expression of cyclooxygenase‐2 (COX‐2), receptors for estrogen (ER), and progesterone (PR), p53, ki67, and neu protein in endometrial cancer. Gynecol Oncol 2005; 98: 383 – 389.
dc.identifier.citedreferenceChatrath P, Scott IS, Morris LS, et al. Aberrant expression of minichromosome maintenance protein‐2 and Ki67 in laryngeal squamous epithelial lesions. Br J Cancer 2003; 89: 1048 – 1054.
dc.identifier.citedreferenceChen ZH, Yu YP, Michalopoulos G, Nelson J, Luo JH. The DNA replication licensing factor miniature chromosome maintenance 7 is essential for RNA splicing of epidermal growth factor receptor, c‐Met, and platelet‐derived growth factor receptor. J Biol Chem 2015; 290: 1404 – 1411.
dc.identifier.citedreferenceTamura T, Shomori K, Haruki T, et al. Minichromosome maintenance‐7 and geminin are reliable prognostic markers in patients with oral squamous cell carcinoma: immunohistochemical study. J Oral Pathol Med 2010; 39: 328 – 334.
dc.identifier.citedreferenceShrestha P, Saito T, Hama S, et al. Geminin: a good prognostic factor in high‐grade astrocytic brain tumors. Cancer 2007; 109: 949 – 956.
dc.identifier.citedreferenceGonzalez MA, Tachibana KE, Chin SF, et al. Geminin predicts adverse clinical outcome in breast cancer by reflecting cell‐cycle progression. J Pathol 2004; 204: 121 – 130.
dc.identifier.citedreferenceDudderidge TJ, Stoeber K, Loddo M, et al. Mcm2, geminin, and KI67 define proliferative state and are prognostic markers in renal cell carcinoma. Clin Cancer Res 2005; 11: 2510 – 2517.
dc.identifier.citedreferenceNishihara K, Shomori K, Tamura T, Fujioka S, Ogawa T, Ito H. Immunohistochemical expression of geminin in colorectal cancer: implication of prognostic significance. Oncol Rep 2009; 21: 1189 – 1195.
dc.identifier.citedreferenceMontanari M, Boninsegna A, Faraglia B, et al. Increased expression of geminin stimulates the growth of mammary epithelial cells and is a frequent event in human tumors. J Cell Physiol 2005; 202: 215 – 222.
dc.identifier.citedreferenceFan Z, Lu Y, Wu X, Mendelsohn J. Antibody‐induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem 1994; 269: 27595 – 27602.
dc.identifier.citedreferenceProkhorova TA, Blow JJ. Sequential MCM/P1 subcomplex assembly is required to form a heterohexamer with replication licensing activity. J Biol Chem 2000; 275: 2491 – 2498.
dc.identifier.citedreferenceMaiorano D, Lutzmann M, Méchali M. MCM proteins and DNA replication. Curr Opin Cell Biol 2006; 18: 130 – 136.
dc.identifier.citedreferenceRomanowski P, Madine MA. Mechanisms restricting DNA replication to once per cell cycle: the role of Cdc6p and ORC. Trends Cell Biol 1997; 7: 9 – 10.
dc.identifier.citedreferenceStoeber K, Tlsty TD, Happerfield L, et al. DNA replication licensing and human cell proliferation. J Cell Sci 2001; 114 ( Pt 11 ): 2027 – 2041.
dc.identifier.citedreferenceForsburg SL. Eukaryotic MCM proteins: beyond replication initiation. Microbiol Mol Biol Rev 2004; 68: 109 – 131.
dc.identifier.citedreferenceGiaginis C, Vgenopoulou S, Vielh P, Theocharis S. MCM proteins as diagnostic and prognostic tumor markers in the clinical setting. Histol Histopathol 2010; 25: 351 – 370.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
hed24670.pdf
Size:
691.7KB
Format:
PDF
View/Open
Name:
hed24670_am.pdf
Size:
1.214MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.